Pisani R J
Division of Thoracic Diseases and Internal Medicine, Mayo Clinic, Rochester, MN 55905.
Mayo Clin Proc. 1993 Apr;68(4):386-92. doi: 10.1016/s0025-6196(12)60137-2.
Evidence that host immunologic function may influence the behavior of lung cancer is accumulating. Non-small-cell lung cancers are heavily infiltrated by host lymphocytes. The fact that monoclonal antibodies have been developed against lung cancer cells implies that such cells express surface antigens and are therefore vulnerable to immune recognition. Failure of the host defense mechanism to control tumor growth may involve (1) reduced natural killer cell activity, (2) inadequate lymphokine-activated killer cell function, or (3) tumor secretion of immunomodulating factors. Basic immunologic research studies of lung cancer are increasing the potential for clinical applications. New monoclonal antibodies have improved both the sensitivity and the specificity of immunohistopathologic analyses of pulmonary specimens. Links between immune function and prognosis in patients with lung cancer have been established. Finally, initial results from protocols that have used tumor-infiltrating lymphocytes, interleukin 2, and tumor vaccines suggest that immunobiologic treatment modalities may be increasingly applicable in patients with lung cancer.
宿主免疫功能可能影响肺癌行为的证据正在不断积累。非小细胞肺癌被宿主淋巴细胞大量浸润。已开发出针对肺癌细胞的单克隆抗体这一事实表明，此类细胞表达表面抗原，因此易受免疫识别。宿主防御机制无法控制肿瘤生长可能涉及：（1）自然杀伤细胞活性降低；（2）淋巴因子激活的杀伤细胞功能不足；或（3）肿瘤分泌免疫调节因子。肺癌的基础免疫学研究增加了临床应用的可能性。新型单克隆抗体提高了肺标本免疫组织病理学分析的敏感性和特异性。肺癌患者免疫功能与预后之间的联系已经确立。最后，使用肿瘤浸润淋巴细胞、白细胞介素2和肿瘤疫苗的方案的初步结果表明，免疫生物学治疗方式可能越来越适用于肺癌患者。
